TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET 27
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 SERVICES LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET END USER GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 PORTERS FIVE FORCES 48
4.2 PESTEL ANALYSIS 49
5 EPIDEMIOLOGY 50
5.1 INCIDENCE OF ALL BY GENDER 50
5.2 TREATMENT RATE 51
5.3 MORTALITY RATE 51
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 52

6 INDUSTRY INSIGHT 53
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 53
6.2 PATENT ANALYSIS 54
6.3 PATENT FLOW DIAGRAM 55
6.4 KEY PATIENT ENROLLMENT STRATEGIES 55
6.5 PRICING STRATEGY 58
7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS 59
8 MARKET OVERVIEW 62
8.1 DRIVERS 64
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 64
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 64
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 65
8.1.4 INCREASE IN R&D ACTIVITIES 65
8.2 RESTRAINTS 66
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 66
8.2.2 STRICT REGULATORY 66
8.3 OPPORTUNITIES: 67
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 67
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 68
8.4 CHALLENGES 68
8.4.1 TIME-CONSUMING PROCEDURE 68
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 69
9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES 70
9.1 OVERVIEW 71
9.2 ECG/HOLTER MEASUREMENTS 75
9.3 BLOOD PRESSURE MEASUREMENTS 75
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 76
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 77
9.4.1.1 1 CONCENTRATIONS 77
9.4.1.2 4 CONCENTRATIONS 77
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 78
9.4.2.1 3 CONCENTRATIONS 78
9.4.2.2 5 CONCENTRATIONS 78
9.4.3 IN VITRO HERG ASSAY 78
9.4.4 OTHERS 78

9.5 CARDIOVASCULAR IMAGING 78
9.6 REAL TIME TELEMETRY MONITORING 79
9.7 CENTRAL OVER-READ OF ECGS 80
9.8 NON-INVASIVE CARDIAC IMAGING 80
9.9 PHYSIOLOGIC STRESS TESTING 81
9.10 THOROUGH QT STUDIES 82
9.11 TQT AND EXPOSURE RESPONSE MODELLING 82
9.12 PLATELET AGGREGATION 83
9.13 OTHERS 84
10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE 85
10.1 OVERVIEW 86
10.2 PHASE I 89
10.3 PHASE II 89
10.4 PHASE III 90
11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE 91
11.1 OVERVIEW 92
11.2 INTEGRATED SERVICES 95
11.3 STANDALONE SERVICES 96
12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER 97
12.1 OVERVIEW 98
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 101
12.3 CONTRACT RESEARCH ORGANIZATIONS 101
12.4 ACADEMIC AND RESEARCH INSTITUTE 102
13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION 103
13.1 OVERVIEW 104
13.2 NORTH AMERICA 109
13.2.1 U.S. 117
13.2.2 CANADA 120
13.2.3 MEXICO 123

13.3 EUROPE 126
13.3.1 GERMANY 134
13.3.2 FRANCE 137
13.3.3 U.K. 140
13.3.4 ITALY 143
13.3.5 SPAIN 146
13.3.6 TURKEY 149
13.3.7 RUSSIA 152
13.3.8 NETHERLANDS 155
13.3.9 SWITZERLAND 158
13.3.10 BELGIUM 161
13.3.11 REST OF EUROPE 164
13.4 ASIA-PACIFIC 165
13.4.1 CHINA 173
13.4.2 JAPAN 176
13.4.3 SOUTH KOREA 179
13.4.4 INDIA 182
13.4.5 AUSTRALIA 185
13.4.6 SINGAPORE 188
13.4.7 THAILAND 191
13.4.8 MALAYSIA 194
13.4.9 INDONESIA 197
13.4.10 PHILIPPINES 200
13.4.11 REST OF ASIA-PACIFIC 203
13.5 SOUTH AMERICA 204
13.5.1 BRAZIL 212
13.5.2 ARGENTINA 215
13.5.3 REST OF SOUTH AMERICA 218
13.6 MIDDLE EAST AND AFRICA 219
13.6.1 SOUTH AFRICA 227
13.6.2 SAUDI ARABIA 230
13.6.3 U.A.E. 233
13.6.4 ISRAEL 236
13.6.5 EGYPT 239
13.6.6 REST OF MIDDLE EAST AND AFRICA 242

14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 243
14.1 COMPANY SHARE ANALYSIS: GLOBAL 243
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 244
14.3 COMPANY SHARE ANALYSIS: EUROPE 245
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 246
15 COMPANY PROFILE 247
15.1 EUROFINS SCIENTIFIC 247
15.1.1 COMPANY SNAPSHOT 247
15.1.2 REVENUE ANALYSIS 248
15.1.3 COMPANY SHARE ANALYSIS 248
15.1.4 PRODUCT PORTFOLIO 248
15.1.5 RECENT DEVELOPMENTS 249
15.1.5.1 AGREEMENTS 249
15.1.5.2 ACQUISITION 249
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 250
15.2.1 COMPANY SNAPSHOT 250
15.2.2 REVENUE ANALYSIS 250
15.2.3 COMPANY SHARE ANALYSIS 251
15.2.4 PRODUCT PORTFOLIO 251
15.2.5 RECENT DEVELOPMENT 251
15.2.5.1 INVESTMENT 251
15.3 KONINKLIJKE PHILIPS N.V. 252
15.3.1 COMPANY SNAPSHOT 252
15.3.2 REVENUE ANALYSIS 252
15.3.3 COMPANY SHARE ANALYSIS 253
15.3.4 PRODUCT PORTFOLIO 253
15.3.5 RECENT DEVELOPMENT 253
15.3.5.1 ACQUISITION 253
15.4 IQVIA 254
15.4.1 COMPANY SNAPSHOT 254
15.4.2 REVENUE ANALYSIS 254
15.4.3 COMPANY SHARE ANALYSIS 255
15.4.4 PRODUCT PORTFOLIO 255
15.4.5 RECENT DEVELOPMENTS 255
15.4.5.1 ACQUISITION 255

15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 256
15.5.1 COMPANY SNAPSHOT 256
15.5.2 REVENUE ANALYSIS 256
15.5.3 COMPANY SHARE ANALYSIS 257
15.5.4 PRODUCT PORTFOLIO 257
15.5.5 RECENT DEVELOPMENTS 257
15.5.5.1 NEW LABORATORY 257
15.5.5.2 ACQUISITION 257
15.6 BANOOK 258
15.6.1 COMPANY SNAPSHOT 258
15.6.2 PRODUCT PORTFOLIO 258
15.6.3 RECENT DEVELOPMENT 258
15.6.3.1 AGREEMENT 258
15.7 BIOTRIAL 259
15.7.1 COMPANY SNAPSHOT 259
15.7.2 PRODUCT PORTFOLIO 259
15.7.3 RECENT DEVELOPMENT 259
15.7.3.1 NEW CENTER OPENING 259
15.8 CELERION 260
15.8.1 COMPANY SNAPSHOT 260
15.8.2 PRODUCT PORTFOLIO 260
15.8.3 RECENT DEVELOPMENT 260
15.8.3.1 NEW CENTER OPENING 260
15.9 CERTARA 261
15.9.1 COMPANY SNAPSHOT 261
15.9.2 REVENUE ANALYSIS 261
15.9.3 PRODUCT PORTFOLIO 262
15.9.4 RECENT DEVELOPMENTS 262
15.9.4.1 CONTRACT 262
15.9.4.2 ACQUISITION 262
15.10 CLARIO 263
15.10.1 COMPANY SNAPSHOT 263
15.10.2 PRODUCT PORTFOLIO 263
15.10.3 RECENT DEVELOPMENT 263
15.10.3.1 PRODUCT EXPANSION 263
15.11 MEDPACE 264
15.11.1 COMPANY SNAPSHOT 264
15.11.2 REVENUE ANALYSIS 264
15.11.3 PRODUCT PORTFOLIO 265
15.11.4 RECENT DEVELOPMENTS 265
15.11.4.1 ACQUISITION 265
15.12 NCARDIA 266
15.12.1 COMPANY SNAPSHOT 266
15.12.2 PRODUCT PORTFOLIO 266
15.12.3 RECENT DEVELOPMENT 266
15.12.3.1 PARTNERSHIP 266
15.13 NEXEL CO., LTD 267
15.13.1 COMPANY SNAPSHOT 267
15.13.2 PRODUCT PORTFOLIO 267
15.13.3 RECENT DEVELOPMENTS 267
15.13.3.1 JOINT VENTURE 267
15.13.3.2 PARTNERSHIP 268
15.14 PHYSIOSTIM 269
15.14.1 COMPANY SNAPSHOT 269
15.14.2 PRODUCT PORTFOLIO 269
15.14.3 RECENT DEVELOPMENT 269
15.14.3.1 PARTNERSHIP 269
15.15 RICHMOND PHARMACOLOGY 270
15.15.1 COMPANY SNAPSHOT 270
15.15.2 PRODUCT PORTFOLIO 270
15.15.3 RECENT DEVELOPMENT 270
15.15.3.1 EVENT 270
15.16 SGS SA 271
15.16.1 COMPANY SNAPSHOT 271
15.16.2 REVENUE ANALYSIS 271
15.16.3 PRODUCT PORTFOLIO 272
15.16.4 RECENT DEVELOPMENT 272
15.16.4.1 ACQUISITION 272
15.17 SHANGHAI MEDICILON INC. 273
15.17.1 COMPANY SNAPSHOT 273
15.17.2 PRODUCT PORTFOLIO 273
15.17.3 RECENT DEVELOPMENTS 273
15.17.3.1 PARTNERSHIP 273
15.17.3.2 PARTNERSHIP 274
16 QUESTIONNAIRE 275
17 RELATED REPORTS 277

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.